---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-025427"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T03:50:24.789733+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aptevo reports 2023 net loss of $17.4M; cash $16.9M; AML trial plan announced

## Summary
- Net loss $17.4M ($1.42/share) vs 2022 net income $8.0M ($1.57/share); cash $16.9M at Dec 31, 2023.
- APVO436 Phase 1b/2 frontline AML trial to start 1H24; interim data expected late 2H24; prior combo showed 91% clinical benefit rate.
- ALG.APV-527 Phase 1 solid tumor trial enrolling; interim results expected 1H24.
- R&D expenses fell to $17.1M (down $0.8M); G&A fell to $11.8M (down $2.1M); $9.65M gain from asset sale.

## SEC filing metadata
- accession: 0000950170-24-025427
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017024025427/0000950170-24-025427-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017024025427/apvo-20240305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-025427
- JSON: https://secwatch.observer/filing/0000950170-24-025427.json
- Plain text: https://secwatch.observer/filing/0000950170-24-025427.txt

## Key facts
- Earnings Releases
  Aptevo Therapeutics Inc. reported financial results for year ended December 31, 2023.
  - Period: year ended December 31, 2023
  - Result: reported results
  source text: Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671584/000095017024025427/0000950170-24-025427-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.